Kaiser Foundation Hospital - South Bay | |
25825 South Vermont Avenue, Harbor City, California 90710 | |
(310) 325-5111 | |
Name | Kaiser Foundation Hospital - South Bay |
---|---|
Type | Acute Care Hospital |
Location | 25825 South Vermont Avenue, Harbor City, California |
Ownership | Voluntary non-profit - Other |
Emergency Services | No |
Medicare ID (CCN) | 050411 |
NPI Number | 1215247762 |
Organization Name | KAISER PERMENENTE |
Address | 25825 Vermont Ave, Harbor City, CA 90710 |
Hospital Type | General Acute Care Hospital |
Phone Number | 310-325-5111 |
News Archive
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States Food and Drug Administration voted to recommend approval of Takeda's vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.
A Northwestern University-led study in the emerging field of nanocytology could one day help men make better decisions about whether or not to undergo aggressive prostate cancer treatments.
Arno Therapeutics, Inc., a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that data from a preclinical study demonstrate its histone-deacetylase (HDAC) inhibitor AR-42 in combination with cisplatin has a synergistic anti-tumor effect in bladder cancer models.
Benefitfocus® and USAble Life announced today a multi-year partnership through 2013 that leverages the Benefitfocus suite of solutions to transform the way group and voluntary benefits are sold, enrolled, billed and serviced.
› Verified 2 days ago
NPI Number | 1336294040 |
Organization Name | KAISER FOUNDATION HOSPITALS |
Doing Business As | KAISER FOUNDATION HOSPITAL - SOUTH BAY |
Address | 25825 South Vermont Ave, Harbor City, CA 90710 |
Hospital Type | General Acute Care Hospital |
Phone Number | 310-325-5111 |
News Archive
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States Food and Drug Administration voted to recommend approval of Takeda's vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.
A Northwestern University-led study in the emerging field of nanocytology could one day help men make better decisions about whether or not to undergo aggressive prostate cancer treatments.
Arno Therapeutics, Inc., a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that data from a preclinical study demonstrate its histone-deacetylase (HDAC) inhibitor AR-42 in combination with cisplatin has a synergistic anti-tumor effect in bladder cancer models.
Benefitfocus® and USAble Life announced today a multi-year partnership through 2013 that leverages the Benefitfocus suite of solutions to transform the way group and voluntary benefits are sold, enrolled, billed and serviced.
› Verified 2 days ago
Able to receive lab results electronically | Not Available |
Able to track patients' lab results, tests, and referrals electronically between visits | Not Available |
News Archive
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States Food and Drug Administration voted to recommend approval of Takeda's vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.
A Northwestern University-led study in the emerging field of nanocytology could one day help men make better decisions about whether or not to undergo aggressive prostate cancer treatments.
Arno Therapeutics, Inc., a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that data from a preclinical study demonstrate its histone-deacetylase (HDAC) inhibitor AR-42 in combination with cisplatin has a synergistic anti-tumor effect in bladder cancer models.
Benefitfocus® and USAble Life announced today a multi-year partnership through 2013 that leverages the Benefitfocus suite of solutions to transform the way group and voluntary benefits are sold, enrolled, billed and serviced.
› Verified 2 days ago
Kaiser Foundation Hospital - South Bay Acute Care Hospital Location: 25825 South Vermont Avenue, Harbor City, California 90710 Phone: (310) 325-5111 |